Price
No data yet.
Social Signal Score
Revenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Daniel Schmitt
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 12
- Beta
- 0.78
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -52.22
Financials
Net Income
$-4.87MEBITDA
$-4.91M-17437.2%Free Cash Flow
$-4.41MEPS (diluted)
$-0.20Shares Outstanding (diluted)
23.87M+78.2%Operating Expenses
$4.91MCash & Debt
$4.43MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-22.23M | $-1.06 |
| 2024 | $0.00 | $-27.29M | $-3.26 |
| 2023 | $0.00 | $-24.74M | $-1.65 |
| 2022 | $0.00 | $-20.16M | $-1.34 |
Valuation
ACTUhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
127Social Signal Score
Mentions (1)
- Newszacks.com·6h ago·Positive
All You Need to Know About Actuate Therapeutics, Inc. (ACTU) Rating Upgrade to Buy Actuate Therapeutics, Inc. (ACTU) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
View source ↗
Earnings
Thu, Nov 12(in 2 months)
Consensus estimate $-0.18 per share
Typical surprise -4.3% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Aug 14$-0.20 vs $-0.21beat
- Thu, May 14$-0.24 vs $-0.23miss
- Thu, Mar 26$-0.18 vs $-0.24beat
- Thu, Nov 13$-0.25 vs $-0.27beat
- Thu, Aug 14$-0.30 vs $-0.19miss
- Thu, May 15$-0.32 vs $-0.30miss
Estimates and results for ACTU via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ACTU officers and directors.
- Bought
- $7.0m
- Sold
- $2.6m
8 trades
14 trades
- Thomson Todd Ssold
- Bios Equity Cof, Lpbought
- Bios Equity Cof, Lpbought
- Kreis Leslie W.bought
- Kreis Leslie W.bought
- Fletcher Aaron G.l.bought
- Fletcher Aaron G.l.bought
- Bios Equity Cof, Lpsold
78 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.